Figure 1. The direct-acting antiviral targets in the hepatitis C virus replication cycle. NS3/4A protease inhibitors target the NS3/4A protease enzyme which is needed for the virus to develop the ...

Occult HCV and HBV infections are recently identified entities whose existence became evident when nucleic acid amplification assays of enhanced sensitivity were employed for the detection of viral ...

Present interferon-based therapy for chronic hepatitis C is limited by both efficacy and tolerability. Telaprevir and boceprevir are the first two direct-acting antiviral drugs (DAAs) that inhibit ...

Hepatitis C virus (HCV) infects an estimated 50 million people worldwide, according to the World Health Organization, and remains a leading cause of cirrhosis and liver cancer. While antiviral drugs ...

Hepatitis C is widely known by name, but far less understood in reality. It's a condition that can exist quietly in the body for years, causing little to no outward sign that anything is wrong, which ...

In previous articles of this series, we’ve discussed several aspects of the hepatitis C virus including the nature of the infection and its distribution both globally and in the United States. Most ...